SECTORS TODAY
Tech XLK -4.89%
Financials XLF -0.76%
Healthcare XLV +0.45%
Energy XLE +1.91%
Industrials XLI -1.60%
Cons. Disc. XLY -0.71%
Cons. Staples XLP +1.41%
Utilities XLU +0.67%
Materials XLB +0.40%
Real Estate XLRE +0.26%
Comm. Svcs XLC -1.29%

Earnings release · PM

Philip Morris International Reports 2026 Third-Quarter & First Nine-Months Results

Philip Morris International Inc. · Filed · SEC Form 8-K, Item 2.02

Philip Morris International Inc. company page Original on SEC.gov ↗

Revenue $11.4 billion +5.5% vs a year ago
EPS $2.12 −4.9% vs a year ago
Guidance —none detected
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete. Please read the original before relying on any figure. Not investment advice.

Why it matters

Revenue climbed 5.5% year on year to $11.4 billion, while EPS fell 4.9% to $2.12. Higher sales with lower EPS can point to rising costs, tax or share-count effects, so the income statement in the original release is worth checking.

Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.

What the company states

Revenue

$11.4 billion +5.5% vs a year ago

…Net revenues increased by 5.5% (7.1% organically) to $11.4 billion, with growth across both smoke-free (up by…
EPS

$2.12 −4.9% vs a year ago

…Reported diluted EPS of $2.12 declined by 4.9%, mainly due to the non-cash fair value adjustment for equity security investments.…
Guidance

No guidance statement detected

Read the original press release on SEC.gov ↗ Filing index ↗

Trend: last 1 reports

All releases →

Revenue growth (YoY)

EPS growth (YoY)

Oct 21, 2026 −4.9%
Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.

Get new research in your inbox

Forensic equity research on US stocks. No spam, unsubscribe anytime.